Press Coverage

Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults

6 June 2024

Mauna Kea Technologies and Metrodora Institute, a leading multispecialty healthcare institute, announced the formation of a new partnership.

This collaboration aims to establish Metrodora Institute as the first U.S. Center of Excellence that will serve as the model of patient care and physician training on the use of Cellvizio for identifying and treating food intolerances in patients suffering from Irritable Bowel Syndrome (IBS).

Read the complete article

Latest News

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

Mauna Kea Technologies Announces 2026 Half-Year Results

Mauna Kea Technologies Announces 2026 Half-Year Results

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

No results found.